Skyhawk expands pivotal FALCON-HD trial for SKY-0515 into U.S., Canada and UK

The company said its Huntington’s disease program now spans more than 10 countries and over 20 sites, with Phase 1/2 enrollment complete and more than 175 patients enrolled.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.